HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Today's Posts

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 11-04-2008, 06:42 PM   #1
Rich66
Senior Member
 
Rich66's Avatar
 
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
Nexavar® May Overcome Resistance to Arimidex

CancerConsultants.com
http://professional.cancerconsultant....aspx?id=42707

Nexavar® May Overcome Resistance to Arimidex® in Breast CancerResearchers from Georgetown University have reported that the addition of Nexavar® (sorafenib) to Arimidex® (anastrozole) helps restore sensitivity to Arimidex among women with breast cancer. These results were recently presented at the 2008 annual American Society of Clinical Oncology (ASCO) breast cancer symposium.
Arimidex is a hormone therapy that prevents the formation of estrogen in the body. It is commonly used among postmenopausal women with hormone-positive breast cancer. Unfortunately, some women can become resistant to Arimidex and others may never respond to Arimidex. Reasons for this lack of response are not clear. Researchers continue to evaluate ways to work around this resistance, such as targeting other biologic pathways associated with cancer.
Nexavar is an orally active, multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma and inoperable hepatocellular carcinoma. Nexavar is also being evaluated in patients with other cancers, including non–small cell lung cancer and melanoma. Used alone, Nexavar has not demonstrated activity for the treatment of breast cancer; however, researchers have speculated that Nexavar may aid in reversing the resistance to Arimidex or other hormone agents.
Researchers from Georgetown University recently conducted a clinical trial to explore the potential effectiveness of the combination of Nexavar and Arimidex in the treatment of advanced breast cancer that has stopped responding to Arimidex. This trial included 27 postmenopausal women with hormone-positive breast cancer who had no more than two prior chemotherapy regimens for their disease and who had stopped responding to prior therapy with Arimidex.
  • Over 26% of patients achieved a partial response or stabilization of their cancer for at least six months.
  • A reduction in endothelial cells in the circulating blood during the first week of treatment predicted a response to therapy.
The researchers concluded that the addition of Nexavar to Arimidex may help overcome resistance to Arimidex in postmenopausal women with hormone-positive advanced breast cancer.
Comments: Ultimately, these results support the idea that targeted therapies may be able to restore sensitivity to certain effective therapies in several types of cancers. Future trials further evaluating this approach are warranted.
__________________

Mom's treatment history (link)
Rich66 is offline   Reply With Quote
 


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 11:18 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter